Year: 2017

Compounds that exhibit high metabolic stability in hepatocytes and subcellular fractions (S9, microsomes and cytosol) can be a challenge for ADME scientists. These in...

Leader in pharmaceutical research and scientific collaboration Originally printed in the Fall 2017 Issue of NewsWave. XenoTech, LLC, which is...

Updated Nov. 6th, 2017 The FDA has released its long-awaited new draft guidance for industry on drug-drug interaction (DDI) studies....

Pooled human hepatocytes can complement a selection of hepatocytes from various species for metabolite profiling, species comparison and evaluation of potential human-specific metabolites. HepatoSure® is the...

The clinically-relevant drug-drug interaction (DDI) between the dyslipidemia drug gemfibrozil and the antidiabetic repaglinide is well-documented throughout the literature. In...

At the time of organ recovery, human livers that have been donated for research are flushed with an ice-cold perfusion...

Check out the recent IQ consortium publication: Considerations from the IQ Induction Working Group in Response to Drug-Drug Interaction Guidances from...

The University of Rhode Island College of Pharmacy’s 5th Annual Transporters in Drug Discovery and Development: Driving Knowledge from Laboratory...

Following the promotion of Dr. Joanna Barbara, PhD, to Vice President of Scientific Operations, Dr. Etsuko Usuki, PhD, has been promoted...

XenoTech’s Analytical Services lab provides researchers with custom method development and method validation, dose solution analysis, in vitro and in vivo metabolite profiling studies, small-molecule non-GLP bioanalysis and...